NA-931 Peptide: Trial Records and What Is Known
NA-931 peptide is an investigational weight loss drug that targets four hormone receptors: IGF-1, GLP-1, GIP and glucagon, though its trial records disagree on whether it is a peptide or a small molecule. It has been tested in phase 1 and phase 2 trials, and the sponsor reports up to 13.8% weight loss in 13 weeks. No peer reviewed paper backs that figure, it has no FDA label, and every result below is what the sponsor reports.
Short answer
- What is NA-931?
- An investigational weight loss drug aimed at four hormone receptors at once: IGF-1, GLP-1, GIP and glucagon. Records disagree on whether it is a peptide or a small molecule.
- Does it work, and is it safe?
- The sponsor reports up to 13.8% weight loss in 13 weeks, with mild nausea and vomiting in 7.3% and diarrhea in 6.3%. No independent group has checked that, and no full paper is published.
- Can you get it?
- Not as an approved medicine. It has no FDA label, and its records are phase 1 and phase 2 trials. Products sold as Bioglutide have no official tie to it.
Sources: NCT06615700; Sponsor abstract SAT-713, PMC12546460; NCT06564753
What Is NA-931: a Peptide or a Small Molecule?
NA-931 is an investigational weight loss drug that its phase 1 ClinicalTrials.gov record (NCT06615700) calls a quadruple agonist of the IGF-1, GLP-1, GIP and glucagon receptors, but the records disagree on whether it is a peptide. The phase 2 registry entry calls it a peptide. A 2025 abstract by the company calls it a small molecule. Here is how each source describes it.
| Source | How it describes NA-931 |
|---|---|
| Phase 1 registry record (NCT06615700) | A quadruple receptor agonist for IGF-1, GLP-1, GIP and glucagon |
| Phase 2 registry record (NCT06564753) | A peptide quadruple receptor agonist |
| 2025 sponsor abstract (PMC12546460) | A small molecule quadruple receptor agonist |
| 2025 sponsor abstract (PMC12725039) | An analog of NA-831 that targets IGF-1, GLP-1 and GIP pathways |
No published paper settles which is right. For other drugs studied on some of the same receptors, see our tirzepatide and retatrutide profiles.
Sources: NCT06615700; NCT06564753; Sponsor abstract SAT-713, PMC12546460; Sponsor abstract, PMC12725039
Does NA-931 Work? What the Sponsor Reports
NA-931's sponsor reports in a 2025 conference abstract (PMC12546460) up to 13.8% weight loss after 13 weeks on its highest dose, or 12.4% compared with placebo. No peer reviewed paper confirms this. These figures come from a company conference abstract, not from a peer reviewed paper.
The sponsor's conference abstracts (PMC12546460 and PMC12725039) report this daily trial dose for their top results:
150 mg daily
Disclaimer: this is a trial dose reported by the sponsor, not label information and not a recommendation. NA-931 has no approved dose. Dose decisions belong with a licensed clinician.
In the 13 week phase 2 study, the sponsor reports dose dependent weight loss of up to 13.8% at 150 mg daily. In a separate 28 day result, the sponsor reports that people on 150 mg a day lost up to 6.8% of body weight, 5.1% more than placebo.
A 2024 abstract adds an animal result. In mice with diet induced obesity and fatty liver disease, the sponsor reports body weight reductions of up to 26%. That is mouse data, and it does not tell you what happens in people.
Sources: Sponsor abstract SAT-713, PMC12546460; Sponsor abstract, PMC12725039; Sponsor abstract, PMC11712949
Is NA-931 Safe? Side Effects the Sponsor Reports
NA-931 safety data come only from the sponsor, whose 2025 phase 2 abstract (PMC12546460) reports mild nausea and vomiting in 7.3% and diarrhea in 6.3% of people on NA-931. No independent safety study exists. In the earlier abstract, it reports mild nausea and diarrhea in 8.3% of people each at the highest dose.
There is no adverse event table on ClinicalTrials.gov and no drug label. That means there is no independent count of side effects to check these numbers against. For the side effects that approved drugs in this class list on their labels, see our GLP-1 side effects guide.
Sources: Sponsor abstract SAT-713, PMC12546460; Sponsor abstract, PMC12725039
Is NA-931 Available? Its Trial Stage
NA-931 is not available as an approved medicine: it has no FDA label, and ClinicalTrials.gov lists only phase 1 and phase 2 trials (NCT06615700, NCT06564753) plus a planned phase 2 trial with tirzepatide (NCT06732245). No phase 3 record was found. None of its trial records has posted results. Six records found in October 2026 mention NA-931: three trial registrations and three conference abstracts written by the company. PubMed has no NA-931 paper.
| Record | Type | What it says | Peer reviewed? |
|---|---|---|---|
| NCT06615700 | Registry record, phase 1 | First in human, single and rising doses, 74 enrolled, randomized, triple masked | No, registry entry |
| NCT06564753 | Registry record, phase 2 | 13 weeks, placebo controlled, 126 enrolled | No, registry entry |
| NCT06732245 | Registry record, phase 2, planned | NA-931 alone or with tirzepatide for 48 weeks, not yet recruiting | No, registry entry |
| PMC12546460 (2025) | Sponsor conference abstract | 13 week weight result, nausea, vomiting and diarrhea rates | No, abstract by the company |
| PMC12725039 (2025) | Sponsor conference abstract | 28 day weight result, nausea and diarrhea at the top dose | No, abstract by the company |
| PMC11712949 (2024) | Sponsor conference abstract | Weight result in mice | No, abstract by the company |
The phase 1 trial was the first test in people. It gave single and rising doses to overweight or obese adults, and its title also covers people with type 2 diabetes. The phase 2 trial ran 13 weeks against placebo in people with obesity and at least one weight related condition.
Sources: NCT06615700; NCT06564753; NCT06732245; Sponsor abstract SAT-713, PMC12546460; Sponsor abstract, PMC12725039; Sponsor abstract, PMC11712949
Is NA-931 Bioglutide, and What Does It Cost?
No ClinicalTrials.gov record or journal abstract links the name Bioglutide to NA-931, and with no FDA label there is no official price. Bioglutide is a name sellers use, not a name in any NA-931 record. Every trial registration and abstract uses only the code NA-931, so nothing official confirms that a product labelled Bioglutide is the trial drug.
For the same reason, there is no official price. NA-931 has no FDA label and has only been studied in clinical trials. Any price online is a seller's price for a product with no official tie to the trial compound. Our guide to checking a certificate of analysis explains what a lab report can and cannot confirm.
Sources: NCT06615700; NCT06564753; NCT06732245
The Planned NA-931 and Tirzepatide Trial
ClinicalTrials.gov record NCT06732245 plans a 48 week phase 2 trial of NA-931 alone or with tirzepatide, to test whether adding NA-931 boosts weight loss, lowers side effects and helps keep muscle. It is the next registered study.
The NCT06732245 registry record lists these planned doses across its 9 arms over 48 weeks:
NA-931 by mouth: 0, 60 mg or 150 mg
Tirzepatide injection: none, 2.5 mg, 5 mg or 10 mg
Disclaimer: these are planned trial doses from a registry record, not a recommendation. Dose decisions belong with a licensed clinician.
The record says 3 tirzepatide doses but lists four values, so the final design may differ. Its status, last verified in December 2025, was not yet recruiting, with an estimated start of 15 August 2026. The record's last update was 27 March 2026, so its status today is not known. The sponsor also says it is advancing NA-931 to phase 3, but no phase 3 record for it was found.
Common Questions
What are the side effects of taking Na-931?+
Only the sponsor has reported them. Its 2025 phase 2 abstract says mild nausea and vomiting in 7.3% and diarrhea in 6.3% of people on NA-931. An earlier abstract says mild nausea and diarrhea in 8.3% each at the highest dose. No independent safety data or label exists, and no results are posted on ClinicalTrials.gov.
What is the price of Bioglutide NA-931 peptide?+
There is no official price. NA-931 is an investigational drug with no FDA label, and the only official records are trials. Prices online are set by sellers. No registry or journal record links the name Bioglutide to NA-931, so a product sold under that name has no official tie to the trial drug.
Is NA-931 a peptide?+
The sources disagree. The phase 2 ClinicalTrials.gov record calls it a peptide quadruple receptor agonist. A 2025 abstract from the sponsor calls it a small molecule. No published paper settles it.
Is NA-931 the same as Bioglutide?+
Sellers use the name Bioglutide for NA-931, but no ClinicalTrials.gov record or journal record confirms that link. All official records use only the code NA-931.
How much weight loss does NA-931 cause?+
The sponsor reports up to 13.8% lower body weight after 13 weeks at 150 mg daily, or 12.4% compared with placebo. These numbers come from a company conference abstract, not a peer reviewed paper. Disclaimer: 150 mg is a trial dose, not a recommendation; dose decisions belong with a licensed clinician.
Is NA-931 FDA approved?+
No. No FDA label exists for NA-931. Its records on ClinicalTrials.gov are phase 1 and phase 2 trials. The sponsor says it is advancing to phase 3, but no phase 3 record for NA-931 was found.
Who makes NA-931?+
The authors of the sponsor abstracts list Biomed Industries, Inc., San Jose, California, as their affiliation.
Sources: Sponsor abstract SAT-713, PMC12546460; Sponsor abstract, PMC12725039; NCT06564753; NCT06615700
Related reading
This guide is for educational purposes only and is not medical advice. It describes what trial registry records and sponsor conference abstracts report about NA-931. NA-931 is an investigational compound that is not approved for any use. Talk to a qualified healthcare professional before making any decision about your health.